Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

respectively, when compared to the three and nine month periods ended April 30, 2008. The increase in product revenue is the result of higher revenues from the sale of Orthovisc(R) in both the three and nine month periods ended April 30, 2009.

License fees and royalty revenue

License fees and royalties totaled $131,000 and $452,000 respectively for the three and nine month periods ended April 30, 2009 and represent a decrease of $112,000 (46.1%) and $61,000 (11.9%) respectively, when compared to the three and nine month periods ended April 30, 2008. In the first quarter of fiscal 2009 and the third quarter of fiscal 2008, license fees and royalty revenues include a termination payment and royalty revenues from Lumera Corporation totaling US$75,000 and US$100,000, respectively. All other license fees and royalties are comprised solely of royalties related to sales of Klean-Prep(TM) outside of Canada.

Cost of sales and margins

Cost of sales totaled $375,000 and $1,160,000 respectively for the three and nine month periods ended April 30, 2009 (three and nine month periods ended April 30, 2008: $326,000 and $908,000 respectively). Margins, on a percentage basis, for the three and nine month periods ended April 30, 2009 remained flat throughout the year at 52.7% (three and nine month periods ended April 30, 2008: 57.9% and 58.4% respectively). The decrease in margins reflect in part, higher purchase costs resulting from a lower Canadian dollar versus the U.S. dollar and increased competitive pricing and product offering in direct competition with Orthovisc(R).

Research & development

Research & development costs for the three and nine month periods ended April 30, 2009 totaled $3,082,000 and $7,584,000, respectively (three and nine month periods ended April 30, 2008: $1,068,000 and $2,879,000 respectively). Of the increase in research and development expenditure
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... Imagine being able to probe and truly ... Being able to read faces and enjoy genuine invisible ... their thoughts and actions like never before. Use ... unique abstract paintings and video, or, play a completely ... as it creates action, dialog, and outcomes based on ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Va., June 27, 2011 A Continuing Medical Education (CME) ... of key risk factors , will be hosted at the ... 2011 from 8:30am to 1pm. "Beating ... Education credits, is designed to help doctors eradicate this disease ...
... JUPITER, Fla., June 27, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... industrial enzyme, bioenergy, and biopharmaceutical industries, announced today ... development and license agreement with a key provider ...
... PharmacoFore, Inc., a privately held biopharmaceutical company developing ... Dr. Joseph Stauffer as Chief Medical Officer & VP, ... Property. Dr. Joseph Stauffer ... Prior to joining PharmacoFore, Dr. Stauffer ...
Cached Biology Technology:Health Diagnostic Laboratory Inc. Sponsors Lecture Series in West Palm Beach, Florida 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 2Dyadic International Enters Into Research and License Agreement With Major Player in the Animal Feed Industry 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 2PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 3PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property 4
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly ... internally and in the cloud. Passwords and their management ... of OTP and standards-based specifications such as those developed ... outmoded use of passwords presents for BYOD, COPE, IoT, ... unified biometric identity protocol. In response ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the University of Houston for a two-day conference to discuss ... , The UH Texas Obesity Research Center (TORC) ... UH M.D. Anderson Library, Rockwell Pavilion. , "We ... that others will see the wealth of obesity research that ...
... hopeful moms-to-be learn, there are important considerations to the ... environment, regular hormonal injections and the timing of the ... procedure. Now a Tel Aviv University researcher ... look at the role that gravity and other biomechanical ...
... team of scientists led by the UK has been given ... frontiers - an ancient lake hidden deep beneath Antarctica,s ice ... the size of Lake Windermere (UK) may have been ... unique forms of life. The team hopes the exploration will ...
Cached Biology News:Texas Obesity Research Center at UH assembles researchers to discuss obesity 2Engineering bouncing babies, 1 at a time 2Final frontier: Mission to explore buried ancient Antarctic lake given green light 2
... The European Collection of Cell Cultures (ECACC) ... West of the West of England, Bristol, ... the quality control of HER2, oestrogen and ... paraffin wax sections of formalin fixed, breast ...
... Electro-4 design allows "4 gels in one ... possible to run 200,samples or more in ... to four,horizontal gels. To ensure even migration, ... number of gels being run. Ideal for,high ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... several isoprostanes produced from arachidonic acid during lipid ... the rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced ... 5 µM, respectively. When infused into the renal ... 4 mg/kg/min, 8-iso PGE2 decreases the GFR and ...
Biology Products: